View source for Equipoise

== What Is Equipoise? ==

'''Equipoise''' refers to a state of genuine uncertainty within the expert medical community regarding whether one treatment is superior to another. It is a fundamental ethical principle in randomized controlled trials (RCTs), ensuring that:
* Participants are not knowingly assigned to an inferior treatment.
* The trial is scientifically justified and can provide valuable new evidence.

=== Types of Equipoise ===
# '''Clinical Equipoise''' (Expert Consensus Equipoise) – Exists when there is genuine uncertainty among clinicians or researchers about the relative benefits and risks of treatment options.
# '''Personal (Individual) Equipoise''' – Exists when a single investigator is personally uncertain about which treatment is best. However, trials rely more on clinical equipoise rather than individual opinions.

== Why Is Equipoise Important in RCTs? ==

=== Ethical Justification ===
* Ensures that no participant is knowingly harmed by being assigned to an inferior treatment.
* Supported by international ethical guidelines, including the ''Declaration of Helsinki'' and ''Belmont Report''.

=== Scientific Validity ===
* Without equipoise, an RCT may lack credibility, as the results would be biased towards a treatment already believed to be superior.
* Ensures that the trial’s findings are genuinely informative for clinical decision-making.

=== [[Informed consent|Informed Consent]] ===
* Participants must be truthfully informed that the trial is being conducted because the best treatment option is unknown.

=== Regulatory Approval & Ethical Oversight ===
* Ethical review boards and regulatory agencies assess whether equipoise exists before approving a trial.

== Challenges to Maintaining Equipoise ==

=== Emerging Evidence During a Trial ===
* Ongoing trials may generate new data that favor one treatment, disrupting equipoise.
* '''Solution''': Implement interim analyses and [[Data Safety and Monitoring Board|Data Safety Monitoring Boards (DSMBs)]] to decide whether to stop or modify the trial.

=== Clinician and Patient Preferences ===
* Some clinicians or patients may strongly prefer one treatment, leading to lower recruitment or non-adherence.
* '''Solution''': Clear communication about equipoise during [[informed consent]].

=== Industry or Funding Bias ===
* Pharmaceutical or industry-sponsored trials may lack true equipoise if there is a strong belief in the superiority of the new treatment.
* '''Solution''': Independent trial oversight committees and transparent study design.

=== Placebo-Controlled Trials ===
* Using a placebo instead of an active comparator may challenge equipoise, especially if an effective standard treatment exists.
* '''Solution''': Placebos are only ethical if there is no proven effective therapy or if withholding treatment does not cause harm.

== Examples of Equipoise in RCTs ==

=== Hypertension Treatment Trials ===
* Equipoise existed when comparing beta-blockers vs. ACE inhibitors before clear superiority was established.

=== COVID-19 Treatment Trials ([https://www.recoverytrial.net/ RECOVERY Trial]) ===
* At the start, there was clinical uncertainty about the effectiveness of treatments like dexamethasone and hydroxychloroquine.
* As evidence emerged, ineffective treatments were discontinued.

=== Breast Cancer Therapy ([https://www.quantumleaphealth.org/for-patients/i-spy-trials/about-i-spy-2/ I-SPY 2 Trial]) ===
* Maintained equipoise by using adaptive platform trial design, allowing new therapies to be tested without bias toward a preferred treatment.

== Loss of Equipoise: When to Stop an RCT? ==
RCTs may be stopped early if:
# One treatment is proven superior or harmful (e.g., early stopping due to clear survival benefits).
# Futility is determined (e.g., the intervention is unlikely to show benefit).
# External evidence resolves uncertainty, making continued [[randomization]] unethical.

== Conclusion ==
Equipoise is critical for conducting ethical and scientifically valid RCTs. It ensures that trials are justified, patients are protected, and results contribute meaningfully to medical knowledge. Maintaining equipoise requires careful trial design, continuous monitoring, and transparent reporting to uphold ethical integrity.
----
=== Bibliography ===

# Freedman B. Equipoise and the [[ethics]] of clinical research. ''New England Journal of Medicine''. 1987;317(3):141–145.
# Miller FG, Brody H. A critique of clinical equipoise: therapeutic misconception in the ethics of clinical trials. ''Hastings Center Report''. 2003;33(3):19–28.
# London AJ. Clinical equipoise: foundational requirement or fundamental error? In: Steinbock B, ed. ''The Oxford Handbook of Bioethics''. Oxford University Press; 2007:571–596.
# Djulbegovic B. The paradox of equipoise: the principle that drives and limits therapeutic discoveries in clinical research. ''Cancer Control''. 2009;16(4):342–347.
# Weijer C, Miller PB. When are research risks reasonable in relation to anticipated benefits? ''Nature Medicine''. 2004;10(6):570–573.

----
''Adapted for educational use. Please cite relevant trial methodology sources when using this material in research or teaching.''